-
Mashup Score: 0Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study - 1 day(s) ago
AbstractBackground. Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for localized disease is still debated.Methods. This
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FRESCO-2 Study Design Overview - 4 day(s) ago
Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC - 12 day(s) ago
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
A phase 2/3 study of GRANITE vaccine in combination with standard therapy shows encouraging early signs of efficacy and safety in patients with metastatic microsatellite-stable colorectal cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A2B530 Receives FDA Orphan Drug Designation in CRC - 2 month(s) ago
The FDA has granted orphan drug designation to A2B530 for the treatment of select patients with colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Colorectal Cancer: Leveraging Awareness and Early Detection - 2 month(s) ago
For Colorectal Cancer Awareness Month, Jedrzej Wykretowicz, MD, PhD, discussed the importance of early detection and taking steps towards the prevention of colorectal cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A2B530 Receives FDA Orphan Drug Designation in CRC - 2 month(s) ago
The FDA has granted orphan drug designation to A2B530 for the treatment of select patients with colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0A2B530 Receives FDA Orphan Drug Designation in CRC - 2 month(s) ago
The FDA has granted orphan drug designation to A2B530 for the treatment of select patients with colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
PURPOSE The intensity of anti-EGFR–based first-line therapy for RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC), once disease control is achieved, is controversial. A de-escalation strategy with anti-EGFR monotherapy represents a potential option to maintain efficacy while reducing cytotoxicity. METHODS In this multicenter, open-label, phase III trial, patients with untreated RAS/BRAF wt mCRC were randomly assigned to receive either fluorouracil, leucovorin, and irinotecan/cetuximab (FOLFIRI/Cet) until disease progression (arm A) or FOLFIRI/Cet for eight cycles followed by Cet alone (arm B). The coprimary end points were a noninferior progression-free survival (PFS) in the modified per-protocol (mPP) population (>eight cycles) and a lower incidence of grade (G) 3-4 adverse events (AEs) for arm B compared with arm A. RESULTS Overall, 606 patients were randomly assigned, with 300 assigned to arm A and 306 to arm B. The median follow-up was 22.3 months. In the mPP population,
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
A retrospective study by Zaanan et al. suggests that adjuvant chemotherapy provides significant survival benefits for high-risk stage II and III small bowel adenocarcinoma. #crcsm @HopitalPompidou Read more here: https://t.co/qw8yYRx1u5 https://t.co/Z3FfTqi2P0